Results 21 to 30 of about 12,400 (143)
Cell Transplantation, 2022 Accumulating data show that N6-methyladenosine (m 6 A) methyltransferase METTL3 and long noncoding RNA MALAT1 act pivotal roles in multiple malignancies including prostate cancer (PCa). However, the role and molecular mechanism underlying METTL3-mediated
Yuanshen Mao +8 more
doaj +1 more source
Biomarker Research, 2023 Background N6-methyladenosine (m6A) methylation is the most abundant chemical posttranscriptional modification of mRNA, and it is associated with the regulation of the immune response to tumors.
Lei Zhan +10 more
doaj +1 more source
Epigenetics, 2023 Doxorubicin (DOX) resistance in breast cancer (BC) poses a huge challenge for the therapeutic effect on BC. Lnc KCNQ1OT1 play crucial roles in chemotherapy resistance.
Zhiyang Zhou +4 more
doaj +1 more source
METTL3 Gains R/W Access to the Epitranscriptome [PDF]
Molecular Cell, 2016 Epitranscriptomic marks are dynamically placed on mRNA by "writer" or "eraser" enzymes, while "readers" modulate their function accordingly. Lin et al. (2016) now report that the N6-methyladenosine:RNA methyltransferase METTL3 is both a writer and a reader, directly enhancing mRNA translation.
Ulrike, Schumann +2 more
openaire +2 more sources
iScience, 2023 Summary: METTL3 is the major writer of N6-Methyladenosine (m6A) and has been associated with controversial roles in cancer. This is best illustrated in urothelial carcinoma of the bladder (UCB), where METTL3 was described to have both oncogenic and tumor-
Jonas Koch +13 more
doaj +1 more source
The RNA Methyltransferase METTL3 Promotes Oncogene Translation [PDF]
Cancer Discovery, 2016 Abstract METTL3 enhances translation independent of methyltransferase activity and methyl reader proteins.
openaire +2 more sources
METTL3 Inhibitors for Epitranscriptomic Modulation of Cellular Processes
ChemMedChem, 2021 Abstract The methylase METTL3 is the writer enzyme of the N 6 ‐methyladenosine (m 6 A) modification of RNA. Using a structure‐based drug discovery approach, we identified a METTL3 inhibitor with potency in a biochemical assay of 280 nM,
Moroz-Omori, Elena V +9 more
openaire +2 more sources
Bibliometric analysis of METTL3: Current perspectives, highlights, and trending topics
Open Life Sciences, 2023 N6-methyladenosine (m6A) is a representative of RNA methylation modification, which plays a critical role in the epigenetic modification process of regulating human diseases.
Liu Hanqi +4 more
doaj +1 more source
Frontiers in Oncology, 2021 Acquired chemoresistance is a major limiting factor in the clinical treatment of glioblastoma (GBM). However, the mechanism by which GBM acquires therapeutic resistance remains unclear.
Jia Shi +11 more
doaj +1 more source
陆军军医大学学报Objective To investigate the molecular mechanism by which methytransferase like3 (METTL3) cooperates with insulin like growth factor 2 mRNA binding protein 2 (IGF2BP2) to regulate HBV replication through N6-methyladenosine (m6A) modifications.
YU Ling, ZHANG Zili, ZENG Rong
doaj +1 more source